Biopharmaceutic Planning in Pediatric Drug Development

Journal Title: The AAPS Journal - Year 2012, Vol 14, Issue 3

Abstract

Pediatric drug development is a required consideration for all drug development programs. Age-appropriate formulations such as suspensions, chewable tablets, oral disintegrating tablets, etc., are typically developed and used in the pediatric clinical studies. However, it is not uncommon to use enabling formulations in the pivotal pediatric clinical study followed by bridging bioavailability and/or bioequivalence studies. Development of age-appropriate formulations is an essential part of pediatric drug development and adds additional biopharmaceutical considerations to an already complex problem. Careful planning of biopharmaceutic data collection during the adult and pediatric development program can contribute significantly to the biopharmaceutic risk assessment and planning of appropriate clinical studies leading to successful development of pediatric formulations.

Authors and Affiliations

Vivek S. Purohit

Keywords

Related Articles

International Guidelines for Bioequivalence of Locally Acting Orally Inhaled Drug Products: Similarities and Differences

The online version of this article (doi:10.1208/s12248-015-9733-9) contains supplementary material, which is available to authorized users.

Rheological Evaluation of Silicon/Carbopol Hydrophilic Gel Systems as a Vehicle for Delivery of Water Insoluble Drugs

The present study analyzed the thickening properties of Carbopol 974 and 971 in a 50:50 mixture of water/Silsense™ A-21, a new cationic silicon miscible in any proportion with water. Samples were prepared by simp...

L-methionine reduces oxidant stress in endothelial cells: Role of heme oxygenase-1, ferritin, and nitric oxide

The amino acid L-methionine is known to exert antioxidant effects by as yet unidentified mechanisms. In the present study, L-methionine led to a concentration-dependent induction of the antioxidant protein heme oxygenase...

Quantitative determination of total methamphetamine and active metabolites in rat tissue by liquid chromatography with tandem mass spectrometric detection

High-throughput liquid chromatography with tandem mass spectrometric detection (LC-MS/MS) methodology for the determination of methamphetamine (METH), amphetamine (AMP), 4-hydroxymethamphetamine (4-OH-METH), and 4-hydrox...

Workshop/conference report—Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays

For quantitative bioanalytical method validation procedure and requirements, there was a relatively good agreement between chromatographic assays and ligand-binding assays. It was realized that the quantitative and quali...

Download PDF file
  • EP ID EP681250
  • DOI  10.1208/s12248-012-9364-3
  • Views 76
  • Downloads 0

How To Cite

Vivek S. Purohit (2012). Biopharmaceutic Planning in Pediatric Drug Development. The AAPS Journal, 14(3), -. https://europub.co.uk./articles/-A-681250